Table 1 Concentrations of 5-FU, CDDP, paclitaxel, docetaxel, olaparib and rucaparib that reduce the viability of UKF-PEC-1, UKF-PeC-3 and its drug-adapted sublines by 50% (IC50) as determined by MTT assay after 120 h of incubation

UKF-PEC1

0.953 ± 0.042

0.268 ± 0.015

2.15 ± 1.75

0.567 ± 0.488

8.69 ± 1.45

20.91 ± 3.73

UKF-PEC1^r5-FU⁵⁰⁰

1.71 ± 0.14

0.623 ± 0.049

2.06 ± 0.54

0.518 ± 0.102

10.07 ± 2.41

16.49 ± 3.62

UKF-PEC1^rCDDP²⁵⁰⁰

0.13 ± 0.03

1.61 ± 0.2

1.61 ± 1.06

0.465 ± 0.202

15.78 ± 0.89

24.07 ± 0.41

UKF-PEC1^rCDDP^2500r5-FU⁵⁰⁰

3.99 ± 0.289

6.66 ± 0.275

1.77 ± 0.59

0.505 ± 0.266

11.61 ± 1.84

22.45 ± 1.38

UKF-PEC3

0.338 ± 0.064

0.943 ± 0.144

2.76 ± 0.18

0.735 ± 0.124

15.79 ± 2.25

34.07 ± 11.39

UKF-PEC3^r5-FU¹⁵⁰⁰

7.83 ± 4.95

2.47 ± 1.37

3.3 ± 0.6

0.913 ± 0.212

32.49 ± 6.39

24.49 ± 1.19

UKF-PEC3^rCDDP²⁰⁰⁰

0.15 ± 0.016

4.18 ± 0.26

1.47 ± 0.09

0.385 ± 0.026

30.97 ± 6.28

21.59 ± 0.86